Thermo Fisher Scientific, Carlsbad, Calif, has launched its first universal quality control for next-generation sequencing (NGS) oncology tests. The AcroMetrix Oncology Hotspot control can be used across laboratories with different NGS instrument platforms, assays, and bioinformatics pipelines to test precision and detect analytical deviations that may arise from reagent and instrument variation. Allowing users to control for more than 500 hotspot mutations, the Oncology Hotspot control contains cancer-associated mutations across 53 genes, including KRAS, BRAF, ERBB2, EGFR and TP53. Users can choose from 500 single nucleotide variants, 18 insertions, 29 deletions, and three complex mutations. Containing both synthetic and genomic DNA, the control has a validated 12-month shelf life at -20°C and is stable over five freeze-thaw events. For more information, visit Thermo Fisher Scientific.
November 4, 2010
June 3, 2011
Moffitt Cancer Center Study Discovers Biological Markers Associated with High-Risk Pancreatic Lesions
February 10, 2015